Certain Restricted Stock Units of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2023.
April 09, 2023
Share
Certain Restricted Stock Units of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2023. These Restricted Stock Units will be under lockup for 61 days starting from 8-FEB-2023 to 10-APR-2023.
Details:
Directors and executive officers have agreed that, without the prior written consent of RBC Capital Markets, LLC on behalf of the underwriters, they will not, during the Lock-Up Period offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive common stock for a period of 60 days after the date of this prospectus supplement.
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
ATYR PHARMA, INC. 
